Genescient Corporation is a California evolutionary genomics company. Its technology is based on the genomics of model organisms (methuselah flies that live over four times longer than regular flies) selectively bred for health and longevity over 30 years. This genomic information is combined with whole-genome data, and massive clinical databases to identify, screen and develop benign therapeutic substances for the treatment of the chronic aging-associated diseases including cardiovascular disease, Type II diabetes, and neurodegenerative diseases. Genescient will also provide its clients with genomic information services that address the genes responsible for the complex genomic trait “rate of aging”.
Sometime this year Genescient will be conducting a trial of a health enhancing compound. Genescient needs people aged 40-75 for the trial. Contact email@example.com if you are in the age range and are interested in volunteering for the trial.
Genescient is now filtering through known safe (FDA approved for some purpose) drugs and non-drugs (like herbs and other natural substances that do not need approval) that can activate what they have identified as longevity genes.
Volunteers for the trial need to be 40-75
* no past history of myocardial infarction (heart attack), cerebra-vascular accidents (stroke) or cancer (People with minor skin cancers can be included in the pilot, people with melanoma are excluded)
* no renal failure (creatine > 2)
* no diagnosed psychiatric disorders, dementia
* no other illness interfering with intestinal absorption of substances or known to severely impair longevity
If you liked this article, please give it a quick review on Reddit, or StumbleUpon.
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.